Article info

Download PDFPDF

EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis
Free

Authors

Citation

Upadhyay N, Ralph L, Ljungcrantz C, et al
EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis

Publication history

  • First published November 1, 2021.
Online issue publication 
November 01, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.